Swiss drug major Novartis AG (NVS) announced detailed results from the Phase III PREVENT trial that evaluates the efficacy and safety of Cosentyx, or secukinumab, in patients with non-radiographic axial spondyloarthritis or nr-axSpA.
from RTT - Biotech https://ift.tt/2O2cTsj
via IFTTT
No comments:
Post a Comment